WO2024161375 - HUMAN ANTI-PD-L2 ANTIBODY AND ITS USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/161375
Publication Date
08.08.2024
International Application No.
PCT/IB2024/050995
International Filing Date
03.02.2024
Title **
[English]
HUMAN ANTI-PD-L2 ANTIBODY AND ITS USES THEREOF
[French]
ANTICORPS ANTI-PD-L2 HUMAIN ET SES UTILISATIONS
Applicants **
MABTREE BIOLOGICS AG
Kugelweg 11e, Basel, Switzerland
4222 Zwingen, CH
Inventors
ALEXANDER, Ratna Monica
Kugelweg 11e, Basel, Switzerland,
4222 Zwingen, CH
ERUTHAYA RAJ, Andhuvan Raj
Kugelweg 11e, Basel, Switzerland,
4222 Zwingen, CH
JAYACHANDRAN, Dr. Rajesh
Kugelweg 11e, Basel, Switzerland,
4222 Zwingen, CH
SOOD, Dr. Chandni
Kugelweg 11e, Basel, Switzerland,
4222 Zwingen, CH
Priority Data
202341007181
04.02.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2141 | |
| EPO | Filing, Examination | 15839 | |
| Japan | Filing | 597 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 8710 |
Total: 27862 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides antibodies or antigen-binding fragments thereof which specifically bind to human PD-L2, and novel complementarity determining regions CDR1, CDR2, and CDR3 for each heavy chain and light chain of said antibodies. Said antibodies or antigen-binding fragments have application in enhancing T-cell function, and treatment of cancer and infectious diseases, acute or chronic.[French]
La présente invention concerne des anticorps ou des fragments de liaison à l'antigène de ceux-ci qui se lient spécifiquement au PD-L2 humain, et de nouvelles régions de détermination de complémentarité CDR1, CDR2 et CDR3 pour chaque chaîne lourde et chaîne légère desdits anticorps. Lesdits anticorps ou fragments de liaison à l'antigène ont une application dans l'amélioration de la fonction des lymphocytes T, et le traitement du cancer et de maladies infectieuses, aiguës ou chroniques.